المؤلفون: M. R. Kuznetsova, I. P. Marchenko, E. E. Fedorov

المصدر: Амбулаторная хирургия, Vol 0, Iss 1-2, Pp 20-25 (2018)

مصطلحات موضوعية: венозные тромбоэмболические осложнения, втэо, профилактика, низкомолекулярные гепарины, дальтепарин, парнапарин, эноксапарин, надропарин, бемипарин, Surgery, RD1-811

وصف الملف: electronic resource

Relation: https://www.a-surgeon.ru/jour/article/view/104; https://doaj.org/toc/2712-8741; https://doaj.org/toc/2782-2591

URL الوصول: https://doaj.org/article/44919e481a9843508fe91a29784f9f7e

المؤلفون: E. P. Panchenko, Е. П. Панченко

المساهمون: This article was published with the support of Pfizer. The article may show the author's position, which may differ from the Pfizer's position, Статья опубликована при поддержке компании «Пфайзер». В статье может быть выражена позиция автора, которая может отличаться от позиции компании «Пфайзер»

المصدر: Aterotromboz = Atherothrombosis; № 1 (2020); 47-54 ; Атеротромбоз; № 1 (2020); 47-54 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2017-3

مصطلحات موضوعية: апиксабан, lower-extremity deep vein thrombosis, pulmonary embolism, direct oral anticoagulants, dalteparin, apixaban, тромбоз глубоких вен нижних конечностей, тромбоэмболия легочной артерии, прямые пероральные антикоагулянты, дальтепарин

وصف الملف: application/pdf

Relation: https://www.aterotromboz.ru/jour/article/view/213/247; Heit J.A., O'FaLLon W.M., Petterson T.M., Lohse C.M., Silverstein M.D., Mohr D.N. Relative Impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162(11):1245-1248. doi:10.1001/archinte.162.11.1245.; Khorana A., DaLaL M., Lin J., ConnoLLy G.C. Incidence and predictors of venous thromboemboLism (VTE) among ambuLatory high-risk cancer patients undergoing chemotherapy in the United States. Cancer. 2013;119(3):648-555. doi:10.1002/cncr.27772.; Lee A.Y., Kamphuisen P.W., Meyer G., Bauersachs R., Janas M.S., Jarner M.F., Khorana A.A. Tinzaparin vs warfarin for treatment of acute venous thromboemboLism in patients with active cancer: a randomized cLinicaL triaL. JAMA. 2015;314(7):677-686. doi:10.1001/jama.2015.9243.; Deitcher S.R., KessLer C.M., MerLi G., Rigas J.R., Lyons R.M., Fareed J. Secondary prevention of venous thromboemboLic events in patients with active cancer: enoxaparin aLone versus initial enoxa-parin foLLowed by warfarin for a 180-day period. Clin Appl Thromb Hemost. 2006;12(4):389-396. doi:10.1177/1076029606293692.; Lee A.Y., Levine M.N., Baker R.I., Bowden C., Kakkar A.K., Prins M. et aL. Low-moLecuLar-weight heparin versus a coumarin for the prevention of recurrent venous thromboemboLism in patients with cancer. N Engl J Med. 2003;349:146-153. doi:10.1056/NEJMoa025313.; Meyer G., Marjanovic Z., VaLcke J., Lorcerie B., GrueL Y., SoLaL-CeLigny P. et aL. Comparison ofLow-moLecuLarweight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729-1735. doi:10.1001/archinte.162.15.1729.; Hull R.D., Pineo G.F., Brant R.F., Mah A.F., Burke N., Dear R. et al. Long-termlow-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med. 2006;119(12):1062-1072. doi:10.1016/j.amjmed.2006.02.022.; Posch F., Konigsbrugge O., Zielinski C., Pabinger I., Ay C. Treatment of venous thromboembolism in patients with cancer: a network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res. 2015;136(3):582-589. doi:10.1016/j.thromres.2015.07.011.; Khorana A., Yannicelli D., McCrae K.R., Milentijevic D., Crivera C., Nelson W.W., Schein J.R. Evaluation of US prescription patterns: are treatment guidelines for cancer-associated venous thromboembolism being followed? Thromb Res. 2016;145:51-53. doi:10.1016/j.thromres.2016.07.013.; Schulman S., Kearon C., Kakkar A.K., Mismetti P., Schellong S., Eriksson H. et al. RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(2):2342-2352. doi:10.1056/NEJMoa0906598.; EINSTEIN Investigators, Bauersachs R., Berkowitz S.D., Brenner B., Decousus H., Gallus A.S., Lensing A.W. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510. doi:10.1056/NEJMoa1007903.; EINSTEIN-PE Investigators, Buller H.R., Prins M.H., Lensin A.W., Decousus H., Jacobson B.F., Minar E. et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-1297. doi:10.1056/NEJMoa1113572.; Prins M.H., Lensing W.A.A., Bauersachs R., van Bellen B., Bounameaux H., Brighton T.A. et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11(1):21. doi:10.1186/1477-9560-11-21.; Agnelli G., Buller H.R., Cohen A., Curto M., Gallus A.S., Jonson M. et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. doi:10.1056/NEJMoa1302507.; Hokusai-VTE Investigators, Buller H.R., Decousus H., Grosso M.A. et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-1415. doi:10.1056/NEJMoa1306638.; Raskob G.E., van E.N., Verhamme P., Carrier M., Di Nisio M., Garcia D. et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378(7):615-624. doi:10.1056/NEJMoa1711948.; Young A.M., Marshall A., Thirlwall J., Chapman O., Lokare A., Hill C. et al. Comparison of an oral factor Xa inhibitor withlow molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol. 2018;36(20):2017-2023. doi:10.1200/JCO.2018.78.8034.; McBane R., Wysokinski W. E., Le-Rademacher J.G., Zemla T., Ashrani A., Tafur A. et al. Apixaban and Dalteparin in Active Malignancy-Associated Venous Thromboembolism: The ADAM VTE Trial. J Thromb Haemost. 2020;18(2):411-421. doi:10.1111/jth.14662.; Konstantinides S.V., Meyer G., Becattini C., Bueno H., Geersing G.-J., Harjola V.-P. et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmo-naryembolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543-603. doi:10.1093/eurheartj/ehz405.; Agnelli G., Becattini C., Meyer G., Murioz A., Huisman M.V., Connors J.M. et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Eng J Med. 2020. doi:10.1056/NEJMoa1915103.; Khorana A.A., Francis C.W., Culakova E., Kuderer N.M., Lyman G.H. Thromboembolism is aleading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost. 2007;5(3):632- 634. doi:10.1111/j.1538-7836.2007.02374.x.; https://www.aterotromboz.ru/jour/article/view/213

الاتاحة: https://www.aterotromboz.ru/jour/article/view/213
https://doi.org/10.21518/2307-1109-2020-1-47-54